|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
Datamonitor, Sep 2004, Pages: 241
Introduction
Despite the plethora of once-daily drugs available for the treatment of ADHD, physicians consistently prescribe immediate release formulations. To bolster revenues, manufacturers must continue to promote awareness of ADHD at all levels, but most also seek to further differentiate their once-daily products from generics and other branded products in the eyes of both the patient and the physician.
Scope
Analysis is based on a survey of 180 prescribing physicians in the seven major markets as well as in-depth interviews with ADHD Key Opinion Leaders
Detailed treatment trees showing the prevalence, diagnosis and treatment rates of ADHD across the seven major markets
Analyzes the first and second-line treatment of children and adolescents with ADHD
Identifies diagnostic and therapeutic unmet needs, highlights how manufacturers can drive patient identification as well as bolster drug prescriptions
Highlights
Datamonitor primary research has identified variances in class- and brand-prescribing preferences among physicians, although prescribing trends generally follow recognized national and international guidelines. However, there is concern over the use of combination therapies in the absence of conclusive clinical trial data.
Only 12.3% of patients are diagnosed, indicating that a huge proportion of patients remain undiagnosed and untreated. Although the awareness of ADHD is ever growing, there are still significant gaps between, knowledge, recognition and referral of the disease. Our highlighted these and provides counteractive strategic recommendations.
Only 20% of patients receive longer-acting, once-daily drugs at first-line, falling to 3% at second-line, with physicians preferring immediate-release formulations. Consequently, Our identified numerous lifecycle strategies to bolster long-acting drug sales.
Reasons to Purchase
Identify commercial opportunities by benchmarking current products and assessing unmet needs and future market potential
Assess the size of the drug-treated population through an understanding of the prevalence of ADHD with comorbid psychiatric and behavioral disorders
Communicate with physicians more effectively, through an understanding of prescribing behavior
Customers who bought this item also bought
Treatment Algorithms 2002: Alzheimer's Disease - Aricept: the physicians choice
Treatment Algorithms 2001: Schizophrenia - The Rise of Atypical Neuroleptics as the Physicians’ Favorite
Treatment Algorithms 2001: Allergic Rhinitis - Unlocking the Real Patient Potential
Treatment Algorithms 2002: Venous Thromboembolism Acute Therapy
Adhd Market: Pestel Analysis and Scenario Based Forecasts
Pipeline Insight: ADHD - Shire Driving Diversity in ADHD
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Treatment Algorithm 2001: Diabetes
Treatment Algorithms 2001: Lung Cancer
Strategic Perspectives 2001: Post Traumatic Stress Disorder - Commercial Potential For Innovative Researchers
Treatment Algorithms 2002: Heart failure - managing chronic and acute patients
Strategic Perspectives 2001: Antidepressant Treatment Strategies - Efficacy Drives Psychiatrist Drug Choice
|
|
|
|
